The US Food and Drug Administration has approved Israeli company Bio-Technology General's recombinant human growth hormone product BioTropin. It is indicated for the treatment of children with small stature. This is the first US approval of a BTG product, and is the latest development in a long battle to bring BioTropin to market.
In January, the US International Trade Commission dismissed a claim by competitor Genentech that BTG's product infringed some process patents. Another patent litigation in a US federal district court is still outstanding, but this will not prevent BTG launching the drug. The market for hGH products in the USA is around $300 million a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze